Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:55
03/25/21
03/25
08:55
03/25/21
08:55
LITE

Lumentum

$79.04 /

-3.45 (-4.18%)

, ENOB

Enochian Biosciences

$3.51 /

-0.25 (-6.65%)

, SYBX

Synlogic

$3.84 /

-0.26 (-6.34%)

, AMWL

Amwell

$18.59 /

-0.41 (-2.16%)

, DRI

Darden

$133.77 /

-2.98 (-2.18%)

, MOV

Movado

$21.62 /

-0.69 (-3.09%)

, RH

RH

$486.00 /

-20.61 (-4.07%)

, IIVI

II-VI

$67.32 /

+1.39 (+2.11%)

, RAD

Rite Aid

$23.33 /

-0.42 (-1.77%)

, EVFM

Evofem

$2.33 /

-0.245 (-9.53%)

, COHR

Coherent

$257.00 /

-2 (-0.77%)

Check out this morning's…

ShowHide Related Items >><<
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

03/18/21
Fly Intel: Top five analyst downgrades
03/18/21 Susquehanna
Lumentum bid for Coherent reaching risk tolerance limits, says Susquehanna
03/18/21 Rosenblatt
Lumentum downgraded to Neutral on Apple headwinds at Rosenblatt
03/18/21 Rosenblatt
Lumentum downgraded to Neutral from Buy at Rosenblatt
ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
AMWL Amwell
$18.59 /

-0.41 (-2.16%)

03/25/21 Cowen
Amwell price target lowered to $35 from $41 at Cowen
03/25/21 Piper Sandler
Amwell price target lowered to $30 from $45 at Piper Sandler
03/23/21 Piper Sandler
Piper remains buyer of telehealth companies despite Amazon competition
03/17/21 Stephens
Amazon news latest sign of rising telehealth competition, says Stephens
DRI Darden
$133.77 /

-2.98 (-2.18%)

03/23/21 RBC Capital
Darden price target raised to $151 from $138 at RBC Capital
03/22/21 Raymond James
Darden price target raised to $155 from $137.50 at Raymond James
03/19/21 Barclays
Darden price target raised to $145 from $131 at Barclays
03/18/21 Wells Fargo
Darden price target raised to $160 from $140 at Wells Fargo
MOV Movado
$21.62 /

-0.69 (-3.09%)

RH RH
$486.00 /

-20.61 (-4.07%)

03/25/21 Wedbush
RH price target raised to $550 from $520 at Wedbush
03/25/21 Wells Fargo
RH price target raised to $575 from $525 at Wells Fargo
03/25/21 Loop Capital
RH price target raised to $600 from $520 at Loop Capital
03/25/21 Cowen
RH price target raised to $600 from $570 at Cowen
IIVI II-VI
$67.32 /

+1.39 (+2.11%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
12/18/20 Deutsche Bank
Rite Aid price target raised to $17 from $9 at Deutsche Bank
11/17/20 Oppenheimer
Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
COHR Coherent
$257.00 /

-2 (-0.77%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

COHR Coherent
$257.00 /

-2 (-0.77%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

  • 25
    Mar
  • 15
    Jan
  • 17
    Sep
  • 02
    Jul
  • 03
    Jun
  • 21
    Apr
LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

Hot Stocks
SRI, Enochian announce complete remission in recurrent glioblastoma patient » 07:58
03/25/21
03/25
07:58
03/25/21
07:58
ENOB

Enochian Biosciences

$3.51 /

-0.25 (-6.65%)

Seraph Research…

Seraph Research Institute, or SRI, and Enochian BioSciences announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The findings were published in the peer-reviewed American Journal of Case Reports. A complete remission response such as this is uncommon for this highly aggressive and deadly form of brain cancer. In compliance with FDA guidance, SRI treated the patient with natural killer, or NK, and dendritic cells, or DC, from a relative who had a partial genetic mismatch. The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90% of glioblastomas. Enochian BioSciences acquired the intellectual property for an approach that is similar to the one used for this clinical outcome. The novel, proprietary strategy includes genetic modification of DCs, potentially increasing the immune response and even more effectively attacking tumors. Enochian BioSciences is actively developing this enhanced immune technology, including proof-of-concept in vivo studies of the potential to clear tumors with a focus on pancreatic cancer. The company said the treatment strategy also could be applicable to several solid tumors.

Over a quarter ago
Hot Stocks
Enochian Biosciences forms SAB for HBV Cure » 08:34
07/27/20
07/27
08:34
07/27/20
08:34
ENOB

Enochian Biosciences

$3.93 /

-0.23 (-5.53%)

Enochian BioSciences…

Enochian BioSciences announced the formation of a Scientific Advisory Board for one of its promising pipelines. Effective immediately, the Hepatitis B Virus Cure SAB will include: Carol Brosgart, MD, Chairperson of the SAB and member of the Enochian BioSciences Board of Directors and Clinical Professor of Medicine, Biostatistics and Epidemiology, University of California, San Francisco; Peter Revill, PhD, Senior Medical Scientist, Victorian Diseases Reference Laboratory, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; and Fabien Zoulim, MD, PhD, Clinical Professor of Medicine at Lyon University; Medical Director, Hepatology Department, Hospices Civils de Lyon; and Scientific Director, Department of Immunology and Virology, INSERM Unit 1052, France.

ShowHide Related Items >><<
ENOB Enochian Biosciences
$3.93 /

-0.23 (-5.53%)

Syndicate
Enochian Biosciences files to sell $50M of common stock  17:15
07/13/20
07/13
17:15
07/13/20
17:15
ENOB

Enochian Biosciences

$3.70 /

-0.19 (-4.88%)

 
ShowHide Related Items >><<
ENOB Enochian Biosciences
$3.70 /

-0.19 (-4.88%)

Hot Stocks
Enochian Biosciences completes FDA INTERACT meeting on ENOB-HV-01 » 07:37
06/08/20
06/08
07:37
06/08/20
07:37
ENOB

Enochian Biosciences

$4.14 /

+0.485 (+13.27%)

Enochian BioSciences…

Enochian BioSciences announced the completion of an Initial Targeted Engagement for Regulatory Advice meeting with the U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies. The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01. ENOB-HV-01 is a novel approach to autologous stem cell transplantation, with the potential to cure HIV by increasing engraftment of gene-modified cells that are resistant to HIV infection. Failure to achieve engraftment has limited the success of other attempts to cure HIV with autologous transplantation. "We considered the meeting to be very successful, with strong alignment between Enochian's approach to developing ENOB-HV-01 and the comments of the FDA reviewers," said Dr. Mark Dybul, Executive Vice-Chair of Enochian BioSciences. "I want to thank the reviewers from FDA CBER OTAT for their time and helpful insight during our meeting. We look forward to advancing our thoughtful and deliberate pre-clinical work during the remainder of this year and into early next, leading to a pre-IND submission in 2021."

ShowHide Related Items >><<
ENOB Enochian Biosciences
$4.14 /

+0.485 (+13.27%)

Hot Stocks
Enochian Biosciences presents abstracts on potential HIV, HBV cures » 08:19
05/13/20
05/13
08:19
05/13/20
08:19
ENOB

Enochian Biosciences

$3.06 /

-1.25 (-29.00%)

Enochian Biosciences…

Enochian Biosciences announces three scientific presentations given yesterday at the Annual Meeting of the American Society of Gene and Cell Therapy. All three abstracts submitted to the conference were accepted for presentation. More than 39 million people live with HIV worldwide. There were approximately 2 million deaths and 1 million new infections last year. Two presentations provide the first description of a novel approach to potentially cure HIV. Genetic modification of cells to overexpress an important enzyme protected them from dying when they were treated with low doses of a chemotherapeutic drug, cyclophosphamide. This innovative strategy resulted in a one hundred and sixty-four percent increase in engraftment of transplanted cells in a mouse model. Two people - the "London Patient" and the "Berlin Patient" have been cured of HIV following transplantation of cells with genetic mutations that prevent HIV infection. However, the transplanted cells were from another person, an approach that carries a high risk of death and significant illness. Attempts to genetically modify and transplant a patient's own cells, that have a much lower risk of serious side effects, have failed due to limited engraftment of the transplanted cells in the bone marrow. The substantial increase in engraftment of genetically modified and transplanted cells in the bone marrow of mice could lead to a clinical approach in humans to potentially cure HIV. Approximately 257 million or five percent of the people in the world are infected with HBV, and nearly 1 million people die per year. At the HEP DART meeting in December 2019, we showed that a novel approach killed up to 97 percent of cells infected with HBV in vitro. Today, we presented new data from several in vivo studies providing a further scientific foundation for the mechanism of action of that killing and further validation of the approach as a potential therapy to cure HBV.

ShowHide Related Items >><<
ENOB Enochian Biosciences
$3.06 /

-1.25 (-29.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.